Business
Business Development Agreement with CorTechs Labs
Business Development Agreement with CorTechs Labs.
About this update from Imaging Biometrics Limited
[{"type":"text","content":"\n \nRNS Number : 8669B IQ-AI Limited 12 June 2019 \n\n \nIQ-AI Ltd\n(\"IQ-AI\" or the \"Company\")\n \nBusiness Development Agreement with CorTechs Labs \n \nIQ-AI Ltd (LON: IQAI), is pleased to announce that the Company's subsidiary, Imaging Biometrics®, LLC (\"IB\"), has entered into a non-exclusive business development and sales agreement with CorTechs Labs (\"CorTechs\"), a global leader in quantitative analysis of brain structures and lesions. The agreement with CorTechs means that IQ-AI's products will benefit from an extended and immediate sales representation in the US and other international markets. The agreement expands CorTechs' portfolio to include IB software's exclusive algorithms that advance clinical understanding of brain tumor pathology by quantitatively distinguishing tumor progression from confounding MR or CT image artifacts. \n \nIB StoneChecker® analysis software is in the final stages of FDA clearance for distribution in the US and will also be added to the CorTechs' portfolio, internationally. StoneChecker provides a critical tool in the management of kidney stone treatment. The software analyses 32 different standardised parameters to distinguish kidney stone size, location and composition to provide conclusive data that determines if lithotripsy is an effective treatment option. \n \nIB software's suite of quantitative and automated tools includes StoneChecker, IB Neuro and IB Delta® Suite. Clinically validated through decades of research, IB Neuro provides critical data about tumor biology that had not previously been available through conventional MR imaging. It is the only image perfusion solution available that automatically generates quantitative (standardised) relative cerebral blood volume (rCBV) maps, independent of scanner, field strength, patient or time point. It is also the only pathologically confirmed neuroimaging software product. IB Delta Suite automates quantitative difference (Delta T1) maps that help clinicians clearly distinguish tumor progression from treatment effect. IB's ...